Can Kratom (*Mitragyna speciosa*) Alleviate COVID-19 Pain? A Case Study

Antonio Metastasio 1,2*, Elisabeth Prevete 3, Darshan Singh 4, Oliver Grundmann 5, Walter C. Prozialeck 6, Charles Veltri 7, Giuseppe Bersani 3 and Ornella Corazza 1,3

1 School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom, 2 NHS Camden and Islington Trust, London, United Kingdom, 3 Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Rome, Italy, 4 Centre for Drug Research, Universiti Sains Malaysia, Minden, Malaysia, 5 Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL, United States, 6 Department of Pharmacology, Midwestern University, Downers Grove, IL, United States, 7 Department of Pharmaceutical Sciences, Midwestern University, Glendale, AZ, United States

Among the symptoms of COVID-19 fever, general malaise, pain and aches, myalgia, fatigue, and headache can affect the quality of life of patients, even after the end of the acute phase of the infection and can be long lasting. The current treatment of these symptoms, also because COVID-19 patients have been asked not to use non-steroidal anti-inflammatory drugs (NSAIDs), in particular ibuprofen are often unsatisfactory. Among the above mentioned symptoms malaise and fatigue seem the most difficult to treat. In this case report we describe the use of kratom (*Mitragyna speciosa*) by a patient with confirmed COVID-19 infection. What we observed was a fast and sustained relieve of the above mentioned symptoms.

Keywords: COVID-19, kratom, opioid, stimulants, new psychoactive substances, new treatments, long covid

BACKGROUND

Viral infections, including the current COVID-19 pandemic, are often associated with fever, general malaise, pain, and aches (1, 2). Of these, fever (98%), cough (76%), dyspnoea (55%), myalgia or fatigue (44%), headache (8%), and haemoptysis (5%) are commonly noted (2). These infections, therefore, even in the milder and non-life threatening forms, can significantly affect the quality of life. Among the various peculiarities of the COVID-19 infection concerns have been raised about the use of non-steroidal anti-inflammatory drugs (NSAIDs), in particular ibuprofen, which at first seemed to worsen the illness, although further studies have disproved this concern (3). As a consequence, several regulatory agencies, including the European Medicines Agency (EMA), at first expressed concerns about its use, as it may deprive patients of an effective treatment for fever and pain with the exception of paracetamol/acetaminophen (3). The debate about NSAID safety is still open. At the beginning of the pandemic, ibuprofen was hypothesized to increase the risk of severe adverse events in COVID-19 patients and a link between NSAIDs and angiotensin-converting enzyme (ACE) 2 receptors upregulation was suggested to be involved (4). Further, Micallef et al. (5) reported that some preclinical evidences, such as immunomodulatory effects or antibiotics efficacy reduction, would support a possible link between NSAIDs and complications in COVID-19 patients. However, data about NSAIDs use in COVID-19 is still inconsistent. In fact, some authors suggested that NSAIDs should be avoided in COVID-19 (6, 7) and others reported that NSAID use has been associated with worse outcomes (4). At the same time, other...
authors highlighted that evidence about the worsening of COVID-19 symptoms by ibuprofen is lacking (8, 9) or only suggested to be prudent in the prescription (10).

Up to date it is possible to say that there is not an unique point of view and the controversial NSAIDs use in COVID-19 is still discussed (8), with recently a positive insight on ibuprofen in COVID-19 disease (11). As consequence there has been a drop in ibuprofen sales (as reported by Glaxo Smith Kline–GSK) in the second quarter of 2020 (12). Considering the burden that COVID-19 infection is imposing to the world population (both in the acute phase and in the so called “long COVID”) we thought important, therefore, to consider also other treatments that could expand our pharmaceutical armamentarium that could alleviate the symptoms of COVID-19 Infection.

In this case report we describe the use of kratom (Mitragyna speciosa), a plant used in traditional medicine in South-East Asia for its therapeutic benefits in self-managing opioid dependence and withdrawal, psychological disorders (e.g., anxiety and depression), and chronic pain (13, 14), and to successfully alleviate COVID-19 related symptoms. Kratom contains more than 40 alkaloids (15, 16), though the majority of its pharmacological properties appear to be related to two of the active compounds: mitragynine and its metabolite 7-hydroxymitragynine (17–19). Kratom is reported to have opioid and non-opioid like effects. In traditional settings in Malaysia and Thailand, rural folks traditionally use kratom as a remedy to treat common health maladies, and kratom consumption practice/tradition do not seem to cause any significant health problems (20–22).

The results of several anonymous online surveys have indicated that the use of kratom products may be useful for the self-treatment of acute and chronic pain (23–25), and in fact, its use is only self-reported to be associated with few adverse effects. Findings from a recent clinical trial confirmed the analgesic properties of kratom in healthy volunteers lasting for approximately 2 h with average blood concentrations of mitragynine at 2,000 ng/mL (26). These results suggest that kratom has the potential to be used as a centrally acting herbal analgesic.

Although kratom is reported to be used as a safe substitute to opioids in self-managing pain, dependence and withdrawal (23–25), it is not free from adverse effects and risks. Kratom dependence has been reported if the product is used in larger quantity over a prolonged period, and negative effects such as sleep problems, depressed mood, diarrhea, and flu-like symptoms including muscle and joint pain can develop with sudden withdrawal (27). Fatalities involving kratom are rare and, autopsy findings indicate that in such instances kratom is concurrently used with illicit substances or anti-depressants, and not kratom per se, or the user had an underlying health condition (28, 29). So far, there have been no reports specifically on fatal kratom overdose incidences (30).

We are aware, however, that there is a lack of robust data about kratom efficacy in humans, to the best of our knowledge there is only one randomized controlled trial that would give some support to kratom’s therapeutic potential in pain. Most of the information available today are the results of surveys and of retrospective studies, in which users claim Kratom’s efficacy in treating acute and chronic pain of different etiologies (23, 24). Other conditions that appear to benefit from kratom are headache (24, 25), back, neck and muscle pain (24, 25), fibromyalgia, arthritis (including autoimmune ones like rheumatoid arthritis), autoimmune disorders like multiple sclerosis (13, 25), and other severe conditions like cancer and chronic inflammatory diseases (25). Some authors have therefore speculated that kratom has a role in the Central Nervous System (CNS) but also as anti-inflammatory (31–33), muscle relaxant (34).

Despite the potential therapeutic benefit, kratom has also severe side effects, that should be always considered when suggesting or only considering a treatment with kratom (35). Among the most severe side effects have been described kratom associated hepatitis (36–39), seizures and coma (40, 41), hypogonadism (42), hypothyroidism (43), posterior reversible leukoencephalopathy (44), fatalities (29, 45) and overdoses (46, 47). It is important to underline, however that most of these events were described mainly in the US and Europe (where Kratom was recently introduced), with a majority of the reported deaths involving the presence of other substances (29), such as benzodiazepine, opioids, antidepressant or antipsychotic agents, alcohol or other substances, e.g., Datura stramonium, cannabinoids, amphetamines (40, 45, 48–51), and other contaminant such as O-desmethyltramadol (52).

There is growing evidence, however, that kratom is safer if used as pure kratom products or brewed herbal decoction in small doses and for a limited period of time. It should be avoided the consumption of large amounts (more than 15 grams per dose) and high frequencies (more than 3 times/day for extended periods of time) because the risk of developing dependence. Several cases have been reported in both Western (53–55), including cases of neonatal abstinence syndrome (56, 57), and Eastern countries (27, 58, 59), where those who used kratom for a long time experienced both physical (e.g., constipation) and psychological (e.g., anxiety) withdrawal symptoms. More recently an article have been published by Muller et al. (60) in which an individual self-prescribing kratom for pain treatment reported an escalation of the dosage needed and eventually developed a dependence.

Considering the conflicting evidence and the paucity of randomized control studies the balance between kratom benefits and risks is not clear yet, but some data suggested that kratom may cause less issues compared to opioids as well as retrospective data showed that kratom reduced the prevalence opioid adverse effects in users (24) and among illicit opioid users (61).

**CASE REPORT**

**Case Presentation**

The subject of this report is a 29 year old male, US citizen of Palestinian descent, who works full-time as a biomedical research technician. His health history is unremarkable, except for the fact that at age 16 he was diagnosed with ulcerative colitis and primary sclerosing cholangitis. Since then, he has been treated successfully with mesalamine (1.2 g, 2 times per day), azathioprine (50 mg,
3 times per day), and ursidiol (300 mg, 2 times per day). The patient also stated: “I didn’t have anxiety or any psychological symptoms. For me, kratom mainly gave improvement in physical reaction.” “It also elevated my mood and made me feel less miserable, to the point where I was able to get out of bed, shower, look at work emails without feeling completely exhausted and drained”; “Kratom helped me more than antibiotic”; “I slept better, I essentially fell asleep immediately. Without kratom, sleep was not nice, with kratom less wake ups, about 6 h.” Over the next 2 weeks the patient’s symptoms gradually subsided and on May 13 he had a televisit with his physician and a follow-up swab test that was negative for COVID-19. The subject was able to end his quarantine and return to work in early June. In a follow-up interview with us, the patient reported that he did not experience any side effects from using kratom, except for a very bad taste when swallowing it. The patient was also able to discontinue kratom use immediately without any evidence of physical or psychological withdrawal symptoms. The patient also informed us that he still had some of the kratom product that he had taken and he agreed to provide us with a sample for chemical analysis.

**Kratom Sample Analysis**

An established quantitative liquid chromatography mass spectrometry method was conducted (62) and found that the sample obtained from the patient is kratom due to the presence of mitragynine (102 mg/g kratom powder) and 7-hydroxymitragynine (0.8 mg/g kratom powder). The extracted kratom sample was analyzed for the presence of 13 opioids and 8 benzodiazepines by comparing the chromatograms to those of the reference mixtures Pain Management Multi-component Opiate Mixture-13 solution and Benzodiazepine Multi-component Mixture-8 solution. These data suggest the sample was not fortified with 7-hydroxymitragynine and there was also no evidence of adulteration with opioids or common benzodiazepines in the sample.

**DISCUSSION**

To the best of our knowledge, this is the first case report that aims to highlight the use of kratom in alleviating COVID-19 infection related symptoms, and pain. Our findings show that short-term kratom use has the potential to alleviate COVID-19 infection symptoms, primarily pain, and did not seem to cause any physical and psychological withdrawal symptoms when kratom was discontinued after short-term use.

Kratom is an evergreen plant indigenous to Southeast Asia. Historically, kratom is a widely used folk remedy or traditional medicine. Kratom prominence grew a decade ago in Europe and the US, when it was chiefly used for its unique medicinal properties in self-managing pain, infections, opioid dependence and withdrawal (25, 63).

The antinociceptive action depends on mitragynine pharmacology: the compound acts as a partial G-protein biased agonist of mu opioid receptors (64, 65), and also as an agonist at other receptors (serotonin, adenosine-2A, dopamine-2, postsynaptic alpha-2 adrenergic) (17, 66). The antinociceptive effects of mitragynine have been studied in animal models.
of clinical trials to identify the safe dosage and pharmacology of mitragynine, monitor, and identify potential side effects of long-term kratom use, and eventually consider a double blind randomized clinical trial to compare its efficacy with the present standard pain relieve treatment.

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

**ETHICS STATEMENT**

Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

**AUTHOR’S NOTE**

We confirm that this work is original and has not been published elsewhere, nor it is currently under consideration for publication elsewhere. It is the output of a collaborative effort among the School of Life and Medical Sciences—University of Hertfordshire (United Kingdom), NHS—Camden and Islington Trust (United Kingdom), Sapienza University of Rome (Italy), Center for Drug Research—Universiti Sains Malaysia (Malaysia), Department of Medicinal Chemistry, College of Pharmacy—University of Florida (United States), Department of Pharmacology, Midwestern University (United States), and Department of Pharmaceutical Sciences—Midwestern University (United States). This publication arises from collaborative activities and staff exchanges among collaborating institutions.

**AUTHOR CONTRIBUTIONS**

AM prepared the original first draft of the manuscript and interviewed the patient with EP and OC. WCP recruited the patient. EP, DS, GB, OG, and WCP contributed to the literature review and the case study analysis. CV carried out the toxicological analysis. OC coordinated all the activities and the preparation of the manuscript. All authors collaborate to the manuscript writing — review and editing.

**REFERENCES**

1. Huang X, Wei F, Hu L, Wan L, Chen K. Epidemiology and clinical characteristics of COVID-19. *Arch. Iran Med.* (2020) 23:268–71. doi: 10.34172/aim.2020.09

2. Jiang F, Deng L, Zhang L, Cai Y, Cheung CW, Xia Z. Review of the clinical characteristics of coronavirus disease 2019 (COVID-19). *J. Gen. Intern. Med.* (2020) 35:1545–49. doi: 10.1007/s11606-020-05762-w

3. Moore N, Carleton B, Blin PV, Bosco-Levy P, Drox C. Does Ibuprofen worsen COVID-19? *Drug Saf.* (2020) 43:611–4. doi: 10.1007/s40264-020-00953-0

4. Pergolizzi Jr JV, Varrassi G, Magnussen P, Lequang JA, Paladini A, Taylor R, et al. COVID-19 and NSAIDs: a narrative review of knowns and unknowns. *Pain Ther.* (2020) 1–6. doi: 10.1007/s40122-020-00173-5

5. Micallef J, Soeiro T, Jonville-Béra AP. Non-steroidal anti-inflammatory drugs, pharmacology, and COVID-19 infection. *Therapie.* (2020) 75:355–62. doi: 10.1016/j.therap.2020.05.003

6. Jean SS, Lee PI, Hsueh PR. Treatment options for COVID-19: the reality and challenges. *J. Microbiol. Immunol. Infect.* (2020) 53:436–43. doi: 10.1016/j.jmii.2020.03.034

7. Lenkens M, de Wit H, Danser AH, Esselink AC, Horikx A, Ten Oever J, et al. Geneesmiddelen bij COVID-19 [medication and comedication in COVID-19 patients]. *Ned. Tijdschr. Geneeskd.* (2020) 164:D4995.

8. Kakodkar P, Kaka N, Baig MN. A comprehensive literature review on the clinical presentation, and management of the pandemic coronavirus disease 2019 (COVID-19). *Cureus.* (2020) 12:e7560. doi: 10.7759/ cureus.7560
15. Shellard EJ. The alkaloids of Mitragyna with special reference to those of Mitragyna speciosa. J. Ethnopharmacol. (2014) 139:132–7. doi: 10.1016/j.drugalcdep.2014.03.017

22. Leong Bin Abdullah MFI, Tan KL, Mohd IS, Yusoff NS, Chear NJY, et al. Motives for using kratom (Mitragyna speciosa). Front. Psychiatry (2020) 9:594. doi: 10.3389/fpsyt.2018.00594

23. Coe MA, Pillitteri JL, Sembower MA, Gerlach KK, Henningfield JE. Kratom (Mitragyna speciosa): user demographics, use patterns, and implications for the opioid epidemic. Drug Alcohol Depend. (2013) 134(Pt A):108–20. doi: 10.1016/j.drugalcdep.2013.08.026

24. Ahmad K, Aziz Z. Mitragyna speciosa use in the northern states of Malaysia: a cross-sectional study. J. Ethnopharmacol. (2012) 141:446–50. doi: 10.1016/j.jep.2012.03.009

25. Vicknasingam B, Choon WT, Rahim AA, Ramachandram D, Singh D, et al. Kratom and pain tolerance: a randomized, placebo-controlled, double-blind study. Yale J. Biol. Med. (2020) 93:229–238.

26. Vicknasingam B, Choon WT, Rahim AA, Ramachandram D, Singh D, et al. Kratom (Mitragyna speciosa): user demographics, use patterns, and implications for the opioid epidemic. Drug Alcohol Depend. (2020) 208:107849. doi: 10.1016/j.drugalcdep.2020.107849

27. Coe MA, Pillitteri JL, Sembower MA, Gerlach KK, Henningfield JE. Kratom as a substitute for opioids: results from an online survey. Drug Alcohol Depend. (2019) 202:24–32. doi: 10.1016/j.drugalcdep.2019.05.005

28. Anwar Bin Abdullah MFI, Tan KL, Mohd IS, Yusoff NS, Chear NJY, et al. Kratom (Mitragyna speciosa) exposures reported to poison centers - United States, 2010-2015. MMWR Morb. Mortal. Wkly. Rep. (2016) 65:748–9. doi: 10.15585/mmwr.mm6529a4

29. Corkery JM, Streep C, Claridge H, Goodair C, Papanti D, Orsoni L, et al. Characteristics of deaths associated with kratom use. J. Psychopharmacol. (2019) 33:1022–3. doi: 10.1177/026988119862530

30. Henningfield JE, Grundmann O, Babin JK, Funt RV, Wang DW, Cone EJ. Risk of death associated with kratom use compared to opioids. Prev. Med. (2019) 128:105851. doi: 10.1016/j.ypmed.2019.105851

31. Raza Azidin RE, Mustafa MR, Mohamed Z, Mohd MA. Anti-Inflammatory Properties of Mitragyna Speciosa Extract. MJS (2005) 24:191–4. Available online at: https://mjs.ium.edu.my/article/view/8971 (accessed October 08, 2020).

32. Shaik Mossadeq WM, Sulaiman MR, Tengku Mohamad TA, Chong HS, Zakaria ZA, Jabit ML, et al. Anti-inflammatory and antinociceptive effects of Mitragyna speciosa Korth methanolic extract. Med. Princ. Pract. (2009) 18:378–84. doi: 10.1007/s11069-009-0199-1

33. Alsaaraf E, Myers J, Culbreth S, Fanikos J. Kratom from head to toe —case reviews of adverse events and toxicities. Curr. Emer. Hosp. Med. Rep. (2019) 7:141–68. doi: 10.1007/s40138-019-00194-1

34. Aldyab M, Ellis PF, Bui R, Chapman TD, Lee H. Kratom-induced cholestatic liver injury mimicking anti-mitochondrial antibody-negative primary biliary cholangitis: a case report and review of literature. Gastroenterol. Res. (2019) 12:211–5. doi: 10.14740/gr1204

35. Fernandes CT, Iqbal U, Tighé SP, Ahmed A. Kratom-induced cholestatic liver injury and its conservative management. J. Investig. Med. High Impact Case Rep. (2019) 7:2324709619836138. doi: 10.1177/2324709619836138

36. Osborne CS, Overstreet AN, Rockey DC, Schreiner AD. Drug-induced liver injury caused by Kratom use as an alternative pain treatment amid an ongoing opioid epidemic. J. Investig. Med. High Impact Case Rep. (2019) 7:2324709619826167. doi: 10.1177/2324709619826167

37. Schimmel J, Dart RC. Kratom (Mitragyna Speciosa) liver injury: a comprehensive review. Drugs. (2020) 80:263–83. doi: 10.1007/s40265-019-01242-6

38. Nelsen JL, Lapoint J, Hodgman MJ, Aldous KM. Seizure and coma following kratom (Mitragyna speciosa Korth) exposure. Toxicol. Obs. (2010) 6:424–6. doi: 10.1016/j.tol.2011.07.007

39. Sheleg SV, Collins GB. A coincidence of addiction to “kratom” and opioid use disorder. Anesthesiology. (2011) 115:538–43. doi: 10.1097/ALN.0b013e3182243d27

40. Domingo O, Roider G, Stöver A, Graw M, Musshoff F, Sachs H, et al. Posterior reversible leukoencephalopathy in a young woman with mitragynine intoxication. J. Neuroimmunol. (2011) 246:96–9. doi: 10.1016/j.jneuroim.2011.09.006

41. Afzal H, Esang M, Rahman S. A case of kratom-induced Seizures. South Med. J. (2011) 104:573–5. doi: 10.1097/SMJ.0b013e318212b90f

42. Castillo A, Payne JD, Nugent K. Posterior reversible leukoencephalopathy syndrome after kratom ingestion. BYUI. Med. Cent. Proc. (2017) 30:355–7. doi: 10.8898/bymi.2017.11929647

43. Sheleg SV, Collins GB. A coincidence of addiction to “kratom” and severe primary hypothryroidism. J. Addict. Med. (2011) 5:300–1. doi: 10.1097/ADM.0b013e3182211afa

44. Neerman MF, Frost RE, Deking J. A drug fatality involving kratom. Case Rep. Drugs. (2020) 80:263–83. doi: 10.1007/s40265-019-01242-6

45. Wong A, Mun M. A case of kratom overdose in a pediatric patient. Case Rep. Pharmacol. (2020) 8:1159. doi: 10.1155/2020/8818095

46. Neerman MF, Frost RE, Deking J. A drug fatality involving kratom. Case Rep. Drugs. (2020) 80:263–83. doi: 10.1007/s40265-019-01242-6

47. Sheleg SV, Collins GB. A coincidence of addiction to “kratom” and severe primary hypothryroidism. J. Addict. Med. (2011) 5:300–1. doi: 10.1097/ADM.0b013e3182211afa

48. Aggarwal G, Robertson E, Mckinlay J, Walter E. Death from kratom toxicity and the possible role of intralipid. J. Intensive Care Soc. (2018) 19:61–3. doi: 10.1177/1751437717721625
50. Gershman K, Timm K, Frank M, Lampi L, Melamed J, Gerona R, et al. Deaths in Colorado attributed to kratom. *N. Engl. J. Med.* (2019) 380:97–8. doi: 10.1056/NEJMc1811055

51. Matson M, Schenk N. Fatality of 33-year-old man involving kratom toxicity. *J. Forensic Sci.* (2019) 64:1933–5. doi: 10.1111/jfsc.14082

52. Arndt T, Claussen U, Güssregen B, Schröfel S, Stürzer B, Werle A, et al. Kratom alkaloids and O-desmethyltramadol in urine of a “Krypton” herbal mixture consumer. *Forensic Sci Int.* (2011) 208:47–52. doi: 10.1016/j.forsciint.2010.10.025

53. Galbis-Reig D. A case report of kratom addiction and withdrawal. *WMJ.* (2016) 115:49–52.

54. Khazaeli A, Jerry JM, Vazirian M. Treatment of kratom withdrawal and addiction with buprenorphine. *J. Addict Med.* (2018) 12:493–5. doi: 10.1097/ADM.0000000000000435

55. Bowe A, Kerr PL. A complex case of kratom dependence, depression, and chronic pain in opioid use disorder: effects of buprenorphine in clinical management. *J Psychoactive Drugs.* (2020) 17:1–6. doi: 10.1080/02791072.2020.1773586

56. Mackay L, Abrahams R. Novel case of maternal and neonatal kratom dependence and withdrawal. *Can. Fam. Physician.* (2018) 64:121–2.

57. Davidson L, Rawat M, Stojanovski S, Chandrasekharan P. Natural drugs, not so natural effects: Neonatal abstinence syndrome secondary to ‘kra tom’. *Neonatal Perinatal. Med.* (2019) 12:109–12. doi: 10.3233/NPM-186317

58. Singh D, Narayanan S, Müller CP, Swogger MT, Rahim AA, Leong Bin Abdullah MFI, et al. Severity of kratom (*Mitragyna speciosa* Korth.) side effects. *Br. J. Pharmacol.* (2018) 175:75–81. doi: 10.1016/j.bjp.2018.07.005

59. Singh D, Narayanan S, Vicknasingam BK, Prozialeck WC, Ramana than S, Zainal H, et al. Severity of pain and sleep problems during kratom (*Mitragyna speciosa* Korth.) cessation among regular kratom users. *J. Psychoactive Drugs.* (2018) 50:445–450. doi: 10.1080/02791072.2018.1511879

60. Müller E, Hillemacher T, Müller CP. Kratom instrumentalization for severe pain self-treatment resulting in addiction - a case report of acute and chronic subjective effects. *Heliyon.* (2020) 6:e04507. doi: 10.1016/j.heliyon.2020.e04507

61. Saref A, Suraya S, Singh D, Grundmann O, Narayanan S, Swogger MT, et al. Self-reported prevalence and severity of opioid and kratom (*Mitragyna speciosa* korth.) side effects. *J. Ethnopharmacol.* (2019) 238:111876. doi: 10.1016/j.jep.2019.111876

62. Prozialeck WC, Edwards JR, Lamar PC, Plotkin BJ, Sigar IM, Grundmann O, et al. Evaluation of the mitragynine content, levels of toxic metals and the presence of microbes in kratom products purchased in the western suburbs of Chicago. *Int. J. Environ. Res. Publ. Health.* (2020) 17:5512. doi: 10.3390/ijerph17155512

63. Eastlick SC, Cornett EM, Kaye AD. Kratom-pharmacology, clinical implications, and outlook: a comprehensive review. *Pain Ther.* (2020) 9:55–69. doi: 10.1007/s40122-020-00151-x

64. Matsumoto K, Hatori Y, Murayama T, Tashima K, Wongsiri pipatana S, Misawa K, et al. Involvement of mu-opioid receptors in antinociception and inhibition of gastrointestinal transit induced by 7-hydroxymitragynine, isolated from Thai herbal medicine *Mitragyna speciosa.* *Eur. J. Pharmacol.* (2006) 549:63–70. doi: 10.1016/j.ejphar.2006.08.013

65. Matsumoto K, Mizowaki M, Suchitra T, Murakami Y, Takayama H, Sakai S, et al. Central antinociceptive effects of mitragynine in mice: contribution of descending noradrenergic and serotonergic systems. *Eur. J. Pharmacol.* (1996) 317:75–81. doi: 10.1016/0014-2999(96)00714-5

66. Boyer EW, Babu KM, Adkins JE, McCurdy CR, Halpern JH. Self-treatment of opioid withdrawal using kratom (*Mitragyna speciosa korth*). *Addiction.* (2008) 103:1048–50. doi: 10.1111/j.1360-0443.2008.02209.x

67. Chin KY, Mark-Lee WF. A review on the antinociceptive effects of *Mitragyna speciosa* and its derivatives on animal model. *Curr. Drug Targets.* (2018) 19:1359–65. doi: 10.2174/1389450118666170925154025

68. Wilson LL, Harris HM, Eans SO, Brice–Tutt A, et al. Lyophilized kratom tea as a therapeutic option for opioid dependence. *Drug Alcohol Depend.* (2020) 216:108310. doi: 10.1016/j.drugalcdep.2020.108310

69. Singh D, Müller CP, Murugaiyah V, Hamid SBS, Vicknasingam BK, Avery B, et al. Evaluating the hematological and clinical-chemistry parameters of kratom (*Mitragyna speciosa*) users in Malaysia. *J. Ethnopharmacol.* (2018) 214:197–206. doi: 10.1016/j.jep.2017.12.017